激素难治性前列腺癌患者停用磷酸雌莫司汀后前列腺特异性抗原急剧下降。

Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.

作者信息

Kobayashi Mizuki, Kuramoto Hiroshi, Ota Junichiro, Fujimoto Naohiro

机构信息

Division of Urology, Moji Rousai Hospital, Kitakyushu, Japan.

出版信息

Int J Urol. 2006 Jul;13(7):1019-21. doi: 10.1111/j.1442-2042.2006.01465.x.

DOI:10.1111/j.1442-2042.2006.01465.x

PMID:16882080

Abstract

Prostate-specific antigen (PSA) decline after discontinuation of estramustine phosphate (EMP) is extremely rare. We report a case with dramatic PSA decline after withdrawal of EMP. A patient with prostate cancer had been treated with luteinizing hormone-releasing hormone and EMP. After refractory, EMP was withdrawn. After withdrawal of EMP, PSA dramatically decreased from 214 ng/mL to 3.71 ng/mL (98.5% decline) and remained low for more than 17 months. In association with PSA decline, lumbago and metastatic lesions improved. We should be aware of this phenomenon and the discontinuation of EMP is recommended in patients with rising PSA after an initial response to EMP.

摘要

停用磷酸雌莫司汀（EMP）后前列腺特异性抗原（PSA）下降极为罕见。我们报告一例停用EMP后PSA显著下降的病例。一名前列腺癌患者接受了促黄体生成素释放激素和EMP治疗。在治疗无效后，停用了EMP。停用EMP后，PSA从214 ng/mL急剧降至3.71 ng/mL（下降98.5%），并在超过17个月的时间里保持在低水平。随着PSA下降，腰痛和转移病灶有所改善。我们应注意到这种现象，对于在最初对EMP有反应后PSA升高的患者，建议停用EMP。